Patents Assigned to The John Hopkins University School of Medicine
-
Patent number: 8124830Abstract: The present invention provides a substantially purified growth differentiation factor (GDF) receptor, including a GDF-8 (myostatin) receptor, as well as functional peptide portions thereof. In addition, the invention provides a virtual representation of a GDF receptor or a functional peptide portion thereof. The present invention also provides a method of modulating an effect of myostatin on a cell by contacting the cell with an agent that affects myostatin signal transduction in the cell. In addition, the invention provides a method of ameliorating the severity of a pathologic condition, which is characterized, at least in part, by an abnormal amount, development or metabolic activity of muscle or adipose tissue in a subject, by modulating myostatin signal transduction in a muscle cell or an adipose tissue cell in the subject.Type: GrantFiled: January 28, 2009Date of Patent: February 28, 2012Assignee: The Johns Hopkins University School of MedicineInventors: Se-Jin Lee, Alexandra C. McPherron
-
Patent number: 8119116Abstract: The present invention relates to methods of treating a cancerous tumor using selective inhibitors of ATP production. The present invention also relates to pharmaceutical preparations comprising such inhibitors and methods for administering them intraarterially directly to a tumor, as well as methods for identifying compositions that selectively inhibitor ATP production for use in the invention.Type: GrantFiled: January 16, 2009Date of Patent: February 21, 2012Assignee: John Hopkins University School of MedicineInventors: Young Hee Ko, Jean-Francois Geschwind, Peter L. Pedersen
-
Patent number: 8097632Abstract: The present invention makes available assays and reagents inhibiting paracrine and/or autocrine signals produced by a hedgehog protein or aberrant activation of a hedgehog signal transduction pathway, e.g., which involve the use of a steroidal alkaloid or other small molecule.Type: GrantFiled: August 20, 2007Date of Patent: January 17, 2012Assignee: Johns Hopkins University School of MedicineInventors: Philip A. Beachy, Jeffery A. Porter, Michael K. Cooper
-
Patent number: 8099151Abstract: A system and method for using magnetic resonance imaging to increase the accuracy of electrophysiologic procedures includes an invasive combined electrophysiology and imaging antenna catheter which includes an RF antenna for receiving magnetic resonance signals and diagnostic electrodes for receiving electrical potentials. The combined electrophysiology and imaging antenna catheter is used in combination with a magnetic resonance imaging scanner to guide and provide visualization during electrophysiologic diagnostic or therapeutic procedures, such as ablation of cardiac arrhythmias. The combined electrophysiology and imaging antenna catheter may further include an ablation tip, and be used as an intracardiac device to deliver energy to selected areas of tissue and visualize the resulting ablation lesions. The antenna utilized in the combined electrophysiology and imaging catheter for receiving MR signals is preferably of the coaxial or “loopless” type.Type: GrantFiled: December 22, 2005Date of Patent: January 17, 2012Assignee: Johns Hopkins University School of MedicineInventors: Henry R Halperin, Ronald D. Berger, Ergin Atalar, Elliot R McVeigh, Albert Lardo, Hugh Calkins, Joao Lima
-
Patent number: 8076073Abstract: The present invention sterol-modified hedgehog polypeptides and functional fragments thereof. Methods of identifying compositions which affect hedgehog activity based on inhibition of cholesterol modification of hedgehog protein are described. In one aspect of the invention, the method provides a means for affecting cholesterol biosynthesis or transport in a cell comprising contacting a cell with an effective amount of a compound that affects hedgehog, thereby affecting cholesterol biosynthesis or transport. The effect may be inhibition or stimulation of cholesterol biosynthesis or transport.Type: GrantFiled: May 20, 2003Date of Patent: December 13, 2011Assignee: The Johns Hopkins University School of MedicineInventors: Philip A. Beachy, Jeffrey A. Porter, Michael K. Cooper
-
Patent number: 8071733Abstract: The present invention provides two novel polypeptides, referred to as the “N” and “C” fragments of hedgehog, or N-terminal and C-terminal fragments, respectively, which are derived after specific cleavage at a G?CF site recognized by the autoproteolytic domain in the native protein. Also included are sterol-modified hedgehog polypeptides and functional fragments thereof. Methods of identifying compositions which affect hedgehog activity based on inhibition of cholesterol modification of hedgehog protein are described.Type: GrantFiled: May 28, 2010Date of Patent: December 6, 2011Assignees: The Johns Hopkins University School of Medicine, University of WashingtonInventors: Philip A. Beachy, Jeffrey A. Porter, Randall T. Moon
-
Patent number: 8071290Abstract: Methods are provided for identifying the presence of cancer cells in a sample by detecting hypermethylation of the promoter region of a GATA-4 transcription factor gene, a GATA-5 transcription factor gene, or both. Methods for ameliorating a cancer by effecting expression of a hypermethylation silenced GATA-4 and/or GATA-5 transcription also are provided.Type: GrantFiled: May 12, 2008Date of Patent: December 6, 2011Assignee: Johns Hopkins University School of MedicineInventors: Stephen B. Baylin, Yoshimitsu Akiyama, James G. Herman
-
Patent number: 8067240Abstract: The present invention provides methods for aiding in the diagnoses of the neoplastic condition of a lung cell and methods of screening for a potential therapeutic agent for the reversal of the neoplastic condition.Type: GrantFiled: November 22, 2010Date of Patent: November 29, 2011Assignees: Esoterix Genetic Laboratories, LLC, Johns Hopkins University School of MedicineInventors: Jin Jen, Gary A. Beaudry, Stephen L. Madden, Arthur H. Bertlesen, David Sidransky
-
Publication number: 20110287058Abstract: The present invention provides a universal immunomodulatory cytokine-expressing bystander cell line, a composition comprising such a cell line and a cancer antigen, a method of making such a cell line, and a method of using such a composition.Type: ApplicationFiled: July 29, 2011Publication date: November 24, 2011Applicant: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINEInventors: Hyam I. LEVITSKY, Ivan BORRELLO
-
Publication number: 20110263519Abstract: The present invention makes available, inter alia, methods and reagents for modulating smoothened-dependent pathway activation. In certain embodiments, the subject methods can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function mutations.Type: ApplicationFiled: July 5, 2011Publication date: October 27, 2011Applicant: JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINEInventors: Philip A. Beachy, James K. Chen, Anssi Jussi Nikolai Taipale
-
Patent number: 8012469Abstract: The present invention provides a universal immunomodulatory cytokine-expressing bystander cell line, a composition comprising such a cell line and a cancer antigen, a method of making such a cell line, and a method of using such a composition.Type: GrantFiled: June 13, 2008Date of Patent: September 6, 2011Assignee: Johns Hopkins University School of MedicineInventors: Hyam I. Levitsky, Ivan Borrello
-
Patent number: 7998946Abstract: The present invention makes available, inter alia, methods and reagents for modulating smoothened-dependent pathway activation. In certain embodiments, the subject methods can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function mutations.Type: GrantFiled: March 28, 2008Date of Patent: August 16, 2011Assignee: Johns Hopkins University School of MedicineInventors: Philip A. Beachy, James K. Chen, Anssi Jussi Nikolai Taipale
-
Patent number: 7989426Abstract: The invention is directed to a method of prophylactically or therapeutically treating choroidal neovascularization, wherein the method comprises directly administering to the eye a therapeutic factor or a nucleic acid sequence that encodes a therapeutic factor, which he expressed to produce the therapeutic factor, to selectively induce apoptosis of endothelial cells associated with neovascularization of the choroid such that choroidal neovascularization is treated prophylactically or therapeutically. The invention also provides a method of prophylactically or therapeutically treating ocular neovascularization, wherein the method comprises directly administering to the eye a nucleic acid sequence encoding a therapeutic factor to promote apoptosis of endothelial cells associated with neovascularization, such that the nucleic acid is expressed thereby producing the therapeutic factor to treat ocular neovascularization prophylactically or therapeutically.Type: GrantFiled: November 12, 2007Date of Patent: August 2, 2011Assignee: Johns Hopkins University School of MedicineInventors: Peter A. Campochiaro, Peter Gehlbach
-
Patent number: 7981603Abstract: The present invention provides methods and kits for identifying an increased risk of developing cancer in a subject. The methods include analyzing a first biological sample, such as a blood sample, from the subject for loss of imprinting of the IGF2 gene. According to the methods a loss of imprinting is indicative of an increased risk of developing cancer. The method can include analyzing genomic DNA from the sample for altered methylation of the IGF2 or the H19 gene. The altered methylation for example includes hypomethylation of a differentially methylated region of IGF2, corresponding to SEQ ID NO:1 and/or a polymorphism or fragment thereof, or hypomethylation of a differentially methylated region of H19 corresponding to SEQ ID NO:6, or a polymorphism, or fragment thereof. In certain aspects, hypomethylation of the H19 DMR or the IGF2 DMR indicates an increased risk of developing colorectal cancer.Type: GrantFiled: July 28, 2003Date of Patent: July 19, 2011Assignee: The Johns Hopkins University School of MedicineInventor: Andrew P. Feinberg
-
Patent number: 7976839Abstract: A transgenic non-human animal of the species selected from the group consisting of avian, bovine, ovine and porcine having a transgene which results in disrupting the production of and/or activity of growth differentiation factor-11 (GDF-11) chromosomally integrated into the germ cells of the animal is provided. Also provided are methods for making such animals, and methods of treating animals, including humans, with antibodies or antisense directed to GDF-11. The animals so treated are characterized by increased muscle tissue and bone tissue.Type: GrantFiled: June 4, 2008Date of Patent: July 12, 2011Assignee: Johns Hopkins University School of MedicineInventors: Se-Jin Lee, Alexandra C. McPherron
-
Patent number: 7964342Abstract: The present invention provides CpG islands and GC rich regions and methods for identifying methylation states for these CpG islands and GC rich regions. The present invention also provides methods for identifying genes regulated by these CpG islands and GC rich regions, and provides methods for identifying a population of CpG islands and GC rich regions in a genome.Type: GrantFiled: December 2, 2002Date of Patent: June 21, 2011Assignee: The Johns Hopkins University School of MedicineInventor: Andrew P. Feinberg
-
Patent number: 7858317Abstract: The invention is directed to a method of diagnosing a cell proliferative disorder of breast tissue by determining the methylation status of nucleic acids obtained from a subject. Aberrant methylation of several genes including TWIST, HOXA5, NES-1, retinoic acid receptor beta (RAR?), estrogen receptor (ER), cyclin D2, WT-1, 14.3.3 sigma, HIN-1, RASSF1A, and combinations of such genes serve as markers of breast malignancy.Type: GrantFiled: October 9, 2008Date of Patent: December 28, 2010Assignee: Johns Hopkins University School of MedicineInventors: Saraswati Sukumar, Ella Evron, William C. Dooley, Nicoletta Sacchi, Nancy Davidson, Mary Jo Fackler
-
Patent number: 7833712Abstract: Methods are provided for detecting a cell proliferative disorder associated with TSLC1 by contacting a proliferating cell of a subject suspected of having the disorder with a reagent that detects TSLC1 and detecting the level of TSLC1 in the proliferating cell. TSLC1 is a single gene whose expression is reduced or absent in A549 and some other NSCLC, hepatocellular carcinoma and pancreatic cancer cell lines. It has further been discovered that TSLC1 expression or suppression is perfectly correlated with promoter methylation state. Restoration of TSLC1 expression to normal or higher levels is sufficient by itself to suppress tumor formation. The invention further provides methods of treating such disorders by contacting cells of a patient suffering from the disorder with a therapeutically effective amount of a reagent that modulates TSLC1 level in the proliferating cells.Type: GrantFiled: September 18, 2006Date of Patent: November 16, 2010Assignees: The John Hopkins University School of Medicine, National Cancer Center Research InstituteInventors: Roger Harper Reeves, Yoshinori Murakami
-
Patent number: 7829333Abstract: The present invention provides transcription factors associated with the hedgehog signaling pathway that are regulated by dephosphorylation by phosphatases. Hedgehog response elements (HRE) that interact with the dephosphorylated transcription factors are also provided as well as methods for identifying compounds that are phosphatase inhibitors. Methods of treating tumors in a subject by modulating the phosphorylation of the transcription factor are also included.Type: GrantFiled: May 22, 2006Date of Patent: November 9, 2010Assignees: The Johns Hopkins University School of Medicine, Baylor College of MedicineInventors: Philip A. Beachy, Ming-Jer Tsai, Sophia Tsai, Venkatesh Krishnan, Chien-Huan Chen
-
Publication number: 20100272760Abstract: A human cell line, which lacks major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens and which has been modified to comprise and express (i) a nucleotide sequence encoding an immunomodulator and (ii) a nucleotide sequence encoding a viral antigen, and a method of inducing or stimulating an immune response in a human to a viral-associated disease or cancer comprising administering to the human (i) the aforementioned human cell line in an amount sufficient to induce or stimulate an immune response to the viral associated disease or cancer, (ii) a human cell line, which lacks MHC-I and MHC-11 antigens and which has been modified to comprise and express a nucleotide sequence encoding an immunomodulator, and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, simultaneously or sequentially in either order, by the same or different routes, in amounts sufficieType: ApplicationFiled: April 8, 2010Publication date: October 28, 2010Applicant: JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINEInventors: Richard F. Ambinder, Yiping Yang, Ivan M. Borrello, Hyam I. Levitsky